{"title":"Investigation of COVID-19 Vaccine Acceptance and Early Side Effects of COVID-19 Vaccine in Hemodialysis Patients","authors":"Kübra Aydın Bahat, Meral Meşe","doi":"10.5152/turkjnephrol.2023.2234305","DOIUrl":null,"url":null,"abstract":"Objective: We aimed to evaluate the acceptance of the COVID-19 vaccines and the frequency of side effects in hemodialysis patients. Methods: Patients receiving regular hemodialysis treatment were included in the study. Patients were asked for their opinions about whether they should have the COVID-19 vaccine. It was recorded which side effects were seen in patients who had received the COVID-19 vaccine. Results: Ninety-two patients who received hemodialysis treatment were evaluated, and 92.4% of them expressed a positive opinion about the COVID-19 vaccine. Patients who were not vaccinated for COVID-19 reported that they were not vaccinated because they thought the vaccine was ineffective. The mean age of patients who did not want to be vaccinated for COVID-19 was lower (P = .019). Among patients who experienced side effects after at least one of the vaccines, and patients who experienced side effects after the first dose of the COVID-19 vaccine, the frequency of side effects was significantly higher in those who received the Pfizer-BioNTech vaccine (P = .001 and P = .001). When the first dose, second dose, and 2 doses of the COVID-19 vaccine were evaluated together, the relationship between increasing age and the decrease in the frequency of side effects was significant (P = .00, P = .001, and P = .015). Conclusion: The vaccination rate against COVID-19 was high in hemodialysis patients, and the most common reason for vaccine opposition was the thought that the vaccine was ineffective. In addition, the frequency of side effects was lower, it was observed that the side effects decreased with age, and the side effects were more frequent in mRNA. © 2023 Turkish Society of Nephrology. All rights reserved.","PeriodicalId":29873,"journal":{"name":"Turkish Journal of Nephrology","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5152/turkjnephrol.2023.2234305","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
血液透析患者新冠肺炎疫苗接受情况及新冠肺炎疫苗早期副作用调查
目的:我们旨在评估新冠肺炎疫苗在血液透析患者中的接受度和副作用发生频率。方法:将接受常规血液透析治疗的患者纳入研究。患者被问及是否应该接种新冠肺炎疫苗的意见。记录了接种新冠肺炎疫苗的患者出现的副作用。结果:对90例接受血液透析治疗的患者进行了评估,其中92.4%的患者对新冠肺炎疫苗持肯定态度。未接种新冠肺炎疫苗的患者报告称,他们未接种疫苗是因为他们认为疫苗无效。不想接种新冠肺炎疫苗的患者的平均年龄较低(P=.019)。在至少接种一种疫苗后出现副作用的患者和第一剂新冠肺炎疫苗后出现不良反应的患者中,接种Pfizer-BioNTech疫苗的患者的副作用频率显著较高(P=.001和P=.001)。当同时评估第一剂、第二剂和两剂新冠肺炎疫苗时,结论:血液透析患者新冠肺炎疫苗接种率高,最常见的疫苗反对原因是认为疫苗无效。此外,副作用的频率较低,观察到副作用随着年龄的增长而减少,并且副作用在mRNA中更频繁。©2023土耳其肾脏病学会。保留所有权利。
本文章由计算机程序翻译,如有差异,请以英文原文为准。